NCT06457919 2026-03-24
A Study of Tinengotinib (TT-00420) in Combination With Standard Treatments in People With Prostate Cancer
Memorial Sloan Kettering Cancer Center
Phase 1/2 Recruiting
Memorial Sloan Kettering Cancer Center
University of Michigan Rogel Cancer Center
Thomas Jefferson University
Institute of Cancer Research, United Kingdom
University of California, San Francisco
Cancer Research UK